The CPS-Ped may be an efficient outcome metric for monitoring disease severity and clinical improvement over time among infants with RSV-related critical illness.

The NIH plans to develop whole-virus vaccines that would provide universal immunity against all strains of influenza and COVID-19.

There was a significant drop in the number of babies hospitalized with RSV this year; a positive news story that can be ...

A 2024-25 flu season that has been classified as high severity has now reached low transmission levels, but 10 new ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related ...

The patient's sample is added to the port, where antibodies targeting the virus fusion protein can bind the antigen in the sample. Capillary action migrates the resultant complex along the strip ...

Of the RSV patients aged 60 or older, 23.0% were admitted to an ICU, 31.5% had acute organ failure, and 9.8% received IMV or ...

As her condition worsened, she developed respiratory issues such as a ... are considered the primary natural reservoir of the virus. Transmission can occur through direct contact with infected ...

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

During the early COVID-19 pandemic, this platform ... An Antiviral Chewing Gum to Reduce Influenza and Herpes Simplex Virus Transmission Apr. 4, 2025 — Low vaccination rates for influenza ...